Heart drug may limit scarring after attack
NCT ID NCT07325955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a drug called trimetazidine can reduce scarring in the heart muscle after a heart attack. 194 people who had a specific type of heart attack took the drug for six months. Researchers used MRI scans to measure the amount of scarring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA general hospital
Beijing, Haidian, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes drug shield the heart during a heart attack procedure?
- Blood condition may predict worse outcomes after heart attack
- Heart attack drug trial halted: could quick cholesterol drop save hearts?
- New balloon treatment could rival standard stent for heart attacks
- New balloon treatment could change heart artery care
- Digital diet plan aims to boost heart pumping power after heart attack